BEST UNLIMITED TURBO LONG CERTIFICATE - GILEAD SCIENCES | Market Closed - Euronext Paris 10:00:00 13/05/2024 pm IST | ||
| 1.18 EUR | +22.92% |
|
| Current month | +26.88% | ||
| 1 month | -21.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 1.18 | +22.92% | 40 |
| 10/24/10 | 0.96 | +26.32% | 56 |
| 09/24/09 | 0.76 | -9.52% | 53 |
| 08/24/08 | 0.84 | -15.15% | 45 |
| 07/24/07 | 0.99 | +33.78% | 42 |
Real-time Euronext Paris
Last update May 13, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| 3K12S | |
| ISIN | DE000SU7JS64 |
| Date issued | 26/01/2024 |
| Strike | 61.36 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 3.83 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.145 € |
|---|---|
| Lowest since issue | 0.67 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.54
USD
Average target price
82.93
USD
Spread / Average Target
+22.78%
- Stock Market
- Certificates
- 3K12S Certificat